Table 2. Univariate results for all 17 prognostic factors evaluated.
| Parameter | HR (95% CI) | P-value |
|---|---|---|
| Age >52 years | 1.4 (0.9–2.0) | 0.11 |
| No. of metastases >2 | 1.4 (1.0–2.0) | 0.069 |
| Male gender | 0.8 (0.6–1.2) | 0.30 |
| Haemoglobin>10.1 | 0.8 (0.5, 1.2) | 0.21 |
| ALC>1.8 | 0.7 (0.4, 1.1) | 0.13 |
| Lung metastases | 0.8 (0.6, 1.2) | 0.33 |
| Bone metastases | 1.1 (0.8, 1.7) | 0.53 |
| Brain metastases | 0.9 (0.5, 1.7) | 0.77 |
| ECOG >1 | 2.6 (1.2–5.6) | 0.016 |
| Albumin>3.5 | 0.5 (0.3, 0.8) | 0.0066 |
| LDH>0.75 × ULN | 2.6 (1.7, 3.8) | <0.0001 |
| WBC>6.1 | 1.8 (1.3,2.6) | 0.0007 |
| Platelet>300 | 1.9 (1.3, 2.8) | 0.0005 |
| ANC>4.9 | 2.2 (1.5, 3.0) | <0.0001 |
| NLR>4 | 2.1 (1.4, 2.9) | <0.0001 |
| Liver metastases | 1.8 (1.2, 2.5) | 0.0013 |
| PLR>498 | 3.0 (1.8, 5.0) | <0.0001 |
Abbreviations: ALC=absolute lymphocyte count; ANC=absolute neutrophil count; CI=confidence interval; ECOG=Eastern Cooperative Group; HR=hazard ratio; LDH=lactate dehydrogenase; NLR=neutrophil/lymphocyte ratio; PLR=platelet/lymphocyte ratio; ULN=upper limit of normal; WBC=white blood cells.
Univariate analysis was performed on 17 clinical factors to evaluate whether any factors were independently associated with overall survival. Hazard ratios with 95% CIs and P values are provided. P<0.05 was considered statistically significant.